Botulinum toxin treatment of patients with oromandibular dystonia in Denmark;Botulinumtoksin-behandling af patienter med oromandibulaer dystoni

Ugeskrift for Laeger

Volumn 162, Issue 48, 2000, Pages 6567-6571

  Erdal, Jesper ^a,b   Werdelin, Lene M ^a   Prytz, Svend ^a   Fuglsang Frederiksen, Anders ^a   Møller, Eigild ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DENMARK; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAM; HUMAN; JAW DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS; DYSTONIC DISORDERS; FEMALE; HISTORY, 16TH CENTURY; HUMANS; MALE; MANDIBLE; MEDICINE IN ART; MIDDLE AGED; PAINTINGS; RETROSPECTIVE STUDIES;

EID: 0034722332     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). J Neurol Neurosurg Psychiatry 1976; 39: 1204-9.
2. Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: primary and secondary forms. I: Fahn S, Marsden CD, Cajne DB et al, eds. Advances in Neurology. Vol. 50: Dystonia 2. New York: Raven Press, 1988: 509-15.
3. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia. Long-term follow-up. Neurology 1999; 53: 2102-7.
4. Meige H. Les convulsions de la face. Revue Neurol (Paris) 1910: 437-43.
5. Tolosa E. Clinical features of Meige's disease. Arch Neurol 1981; 38: 147-51.
6. Jankovic J, Ford J. Blepharaspasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983; 13: 402-11.
7. Blitzer A, Greene PE, Brin MF, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989; 98: 93-7.
8. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-9.
9. Brin MF, Blitzer A, Herman S, Stewart C. Oromandibular dystonia: treatment of 96 patientswith botulinum toxin type A. I: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker Inc., 1994: 429-35.
10. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996; 41: 51-65.
11. Østergaard L, Fuglsang-Frederiksen A, Sjö O, Werdelin L, Winkel H. Quantitative EMG in cervical dystonia. Electromyogr Clin Neurophysiol 1996; 36: 179-85.
12. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616-23.
13. Van den Berg P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle & Nerve 1995; 18: 720-9.
14. Defazio G, Lepore V, Abruzzese G, Barontini E, Berardelli A, Carcaceni T et al. Reliability among neurologists in the severity assessment of blepharospasm and oromandibular dystonia: a multicenter study. Mov Disord 1994; 9: 616-21.